ABSTRACT
Retapamulin (previously SB-275833) is the first topical antibiotic developed from the new class of semisynthetic pleuromutilin class of antimicrobial agents. It was approved by the United States Food and Drug Administration (FDA) in 2007 for the topical treatment of impetigo in patients 9 months old and above under the name brand Altabax and obtained European marketing authorization in 2007, as Altargo 10 mg/g ointment, for the short-term treatment of impetigo and infected small lacerations, abrasions, or sutured wounds for adults and children above the age of 9 months (GlaxoSmithKline, 2015).
